Compare VanEck Semiconductor ETF (SMH) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Summit Therapeutics Inc — how do they compare? VanEck Semiconductor ETF trades at $574.21, while Summit Therapeutics Inc trades at $17.55 (market cap $13.79B). The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMH | SMMT | |
|---|---|---|
52-Week High | $668.91 | $26.38 |
52-Week Low | $300.83 | $12.43 |
Market Cap | — | $13.79B |
Sector | — | Health |
Enterprise Value | — | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH (VanEck Semiconductor ETF) trades at $573.73, up 1.19% with strong bullish technical signals from moving averages. The ETF benefits from sustained AI-driven semiconductor demand, highlighted by NVIDIA's $12.9B Hugging Face acquisition and robust earnings. Technical indicators show support at $570 and resistance at $579, with RSI levels in neutral territory suggesting balanced momentum.
Outlook remains positive amid AI infrastructure expansion, though risks include potential US tariffs and market volatility. Institutional interest is growing, with Greenland Capital adding a $678,000 position. The ETF's exposure to leading chipmakers positions it for continued growth, but investors should monitor regulatory developments and competitive dynamics.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
